Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics

October 9, 2023, San Diego and Shanghai - Sirius Therapeutics today announced that it has completed US$60 million Series-B financing to advance clinical development of the Company’s novel siRNA therapeutics and the continued innovation of the next-generation RNA delivery technologies. This financing round was led by Hankang Capital, followed by Delos Capital, while OrbiMed and Creacion Ventures, two existing lead investors also joined. To date, Sirius has successfully raised nearly US$100 million in total.

Dr. Qunsheng Ji, CEO of Sirius Therapeutics, said, “We truly appreciate our investors’ continued support to our team, platform, strategy, and the recognition of the company’s achievements since its inception. The nearly US$100 million funding we have received thus far will be allocated to advance the human studies of our investigational siRNA drugs, to further expand our competitive pipeline, and ultimately to accelerate the development of high-quality and affordable siRNA therapeutics for the benefit of patients around the world.”

Mr. Kevin Quanhong Yuan, the Founding Partner of Hankang Capital said, “RNA-silencing therapeutics has potentials to transform the standard of care for the treatment of chronic disorders, in particular cardiovascular diseases. Sirius represents the next generation of unique insights into CVD treatment, with its exceptional management team, state-of-art oligonucleotide platform, as well as highly differentiated pipeline. We are excited to lead this round of financing to empower Sirius’ endeavor to deliver paradigm-shifting therapeutics to patients with cardiovascular worldwide.’’

Mr. David Guowei Wang, Partner and Senior Managing Director, Asia, at OrbiMed and Chairman of Sirius Therapeutics, commented, “siRNA medicine has already shown its compelling potential and therapeutic utility. Sirius is dedicated to developing a new-generation of RNA therapeutics and a portfolio of practice-changing solutions for the management of chronic diseases. Adopting a unique approach to target selection and product development, Sirius has already built a highly innovative pipeline with well-balanced risk and a proprietary technology platform. We hope its innovative technology and products will yield more breakthroughs for the management of chronic diseases.”

About Sirius Therapeutics

Sirius is a biotech company developing novel siRNA therapies for the patients particularly with cardiovascular diseases around the world. Founded in 2021, Sirius established its Research Center in the United States and Translational Center in China dedicating to paradigm-shift solutions for the treatment and management of chronic diseases. For more information, please visit its website www.siriusrna.com.

About OrbiMed

OrbiMed is a healthcare investment firm, with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, London, Herzliya and other key global markets.

About Creacion Ventures

Creacion Ventures is a cross-border venture investment USD fund with offices in Boston, the United States, and Shanghai, China. The fund specializes in early-stage investment in the biopharmaceutical and medical devices sectors and discovering industry-shaping opportunities in the life science and healthcare space, with a particular focus on building incubator platforms in China and the U.S. Creacion Venture has a wealth of experience in cultivating biotech startups.

About Hankang Capital

Hankang Capital is a healthcare-dedicated venture capital fund based in China and with a global vision. To fulfill Hankang’s mission in empowering biomedical innovation to safeguard human health, Hankang Capital has established strong partnership with top-notch entrepreneurs and pioneering scientists to develop breakthrough therapies addressing significant unmet medical needs. With AUM close to RMB 5 billion, Hankang Capital has invested in multitude of companies, many of which have grown into industry leaders in their respective sectors.

About Delos Capital

Delos Capital is a healthcare-focused fund, investing in growth platforms in Greater China and relevant innovation in the U.S. in both therapeutics and medical technology areas. Delos Capital seeks to achieve returns through supporting these companies in their development and also helping to create additional value from collaboration between these companies. With the extensive expertise and experience in both Greater China and the US, Delos Capital believes that it is well positioned to help with such collaboration. Delos Capital currently manages two funds, with over US$ 330 million in total capital under management.